BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10723578)

  • 1. Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years.
    Kulkarni S; Powles R; Treleaven J; Singhal S; Horton C; Sirohi B; Bhagawati N; Tait D; Saso R; Killick S; Pinkerton R; Atra A; Meller S; Mehta J
    Bone Marrow Transplant; 2000 Feb; 25(4):365-70. PubMed ID: 10723578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
    Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
    Bone Marrow Transplant; 2000 Mar; 25(5):483-7. PubMed ID: 10713623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.
    Helenglass G; Powles RL; McElwain TJ; Lakhani A; Milan S; Gore M; Nandi A; Zuiable A; Perren T; Forgeson G
    Bone Marrow Transplant; 1988 Jan; 3(1):21-9. PubMed ID: 3048467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.
    Singhal S; Powles R; Treleaven J; Horton C; Swansbury GJ; Mehta J
    Bone Marrow Transplant; 1996 Dec; 18(6):1049-55. PubMed ID: 8971372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
    Hunter HM; Peggs K; Powles R; Rahemtulla A; Mahendra P; Cavenagh J; Littlewood T; Potter M; Hunter A; Pagliuca A; Williams CD; Cook G; Towlson K; Marks David I; Russell NH;
    Br J Haematol; 2005 Feb; 128(4):496-502. PubMed ID: 15686458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
    Inamoto Y; Kuwatsuka Y; Tsujimura A; Tokunaga M; Oba T; Miyamura K; Kodera Y
    Rinsho Ketsueki; 2006 Jan; 47(1):9-15. PubMed ID: 16479977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
    Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A
    Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation.
    Inamoto Y; Nishida T; Suzuki R; Miyamura K; Sao H; Iida H; Naoe T; Maruyama F; Hirabayashi N; Hamaguchi M; Iseki T; Kami M; Yano K; Takeyama H; Morishita Y; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2007 Jan; 39(1):25-30. PubMed ID: 17115063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
    Yoshimi A; Nannya Y; Sakata-Yanagimoto M; Oshima K; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
    Borgmann A; Zinn C; Hartmann R; Herold R; Kaatsch P; Escherich G; Möricke A; Henze G; von Stackelberg A;
    Eur J Cancer; 2008 Jan; 44(2):257-68. PubMed ID: 17981026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood.
    Cohen A; Rovelli A; van Lint MT; Merlo F; Gaiero A; Mulas R; Balduzzi A; Corti P; Uderzo C; Bacigalupo A
    Bone Marrow Transplant; 2001 Dec; 28(12):1125-8. PubMed ID: 11803353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.
    Qamruddin AO; Oppenheim BA; Guiver M; Mutton KJ; Chopra R
    Bone Marrow Transplant; 2001 Feb; 27(3):301-6. PubMed ID: 11277178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.